Compare GCBC & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GCBC | RLMD |
|---|---|---|
| Founded | 1889 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.0M | 461.9M |
| IPO Year | 1998 | 2012 |
| Metric | GCBC | RLMD |
|---|---|---|
| Price | $33.95 | $3.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | 23.5K | ★ 1.2M |
| Earning Date | 10-30-2026 | 11-12-2026 |
| Dividend Yield | ★ 1.28% | N/A |
| EPS Growth | 31.69 | ★ 45.28 |
| EPS | ★ 2.41 | N/A |
| Revenue | ★ $4,117,000.00 | $13,070.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.24 | ★ N/A |
| Revenue Growth | 11.06 | ★ 154.83 |
| 52 Week Low | $21.38 | $1.98 |
| 52 Week High | $36.33 | $8.00 |
| Indicator | GCBC | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 31.66 |
| Support Level | $34.05 | $3.16 |
| Resistance Level | $35.84 | $4.44 |
| Average True Range (ATR) | 0.61 | 0.19 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 72.62 | 13.00 |
Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.